Скачать с ютуб Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA в хорошем качестве

Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA

Catherine Broome, MD, Georgetown University Hospital, Washington, DC, comments on the findings of a post-hoc analysis of safety data from the Phase III CARDINAL (NCT03347396) and CADENZA (NCT03347422) trials, which investigated the use of sutimlimab in patients with cold agglutinin disease (CAD) with and without a recent history of transfusion, respectively. Sutimlimab is a first-in-class, humanized, monoclonal antibody that inhibits the classical complement pathway (CP). This agent was generally well tolerated, with no unexpected adverse events emerging. The type and frequency of treatment-emergent adverse events (TEAE) recorded were consistent with those observed in a typical population with CAD, in which patients tend to be older with multiple co-morbidities. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.